Lilly opens a broader expanded-access program for retatrutide

Eli Lilly said on Aug. 3, 2026, that it has built an expanded access program letting more patients apply to receive retatrutide, an obesity drug that has not yet been approved by the Food and Drug Administration ^[1][2]. The move follows reporting that the company had earlier granted the same kind of early access to a single 79-year-old patient, a decision that drew scrutiny once it became public ^[1].

A Lilly spokesperson said the company believes it is "medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA's guidance" for a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial ^[1][2]. To qualify, patients must be 18 or older, have obesity that has not responded even to the highest approved dose of an existing obesity therapy, and have at least two serious or life-threatening obesity-related health problems for which they are already being treated ^[2]. Patients also must not be able to join an ongoing trial of retatrutide or a similar experimental drug ^[2].

Retatrutide is designed to act on three metabolic hormones — GLP-1, GIP, and glucagon — while Lilly's approved injectable Zepbound (tirzepatide) targets only two of those, GLP-1 and GIP ^[2]. Lilly reported in July that an 80-week trial of adults with severe obesity and existing heart disease showed an average weight loss of 22.6% among those on the highest weekly dose of retatrutide ^[2]. The company said it plans to submit retatrutide for FDA approval in the first quarter of next year ^[2].

Some doctors have pushed back on how Lilly is handling early access, arguing that offering an unapproved obesity drug outside of clinical trials sets a difficult precedent for the field, according to STAT's reporting on the episode ^[1]. That reporting followed doctors who had asked Lilly for the same kind of access already granted to the 79-year-old patient and had not received a response before the company's Aug. 3 announcement ^[1].

Why it matters for patients

For people with obesity and serious related health problems — such as heart disease — who have already tried the highest doses of approved drugs like Zepbound or Wegovy without success, this program could offer a path to a drug that is still in testing ^[2]. But expanded access, sometimes called compassionate use, is meant for a narrow group of patients who meet strict criteria and cannot get into a clinical trial ^[2]. It is not the same as FDA approval, and it does not mean retatrutide is available to the general public or that insurance will cover it.

The criticism from some physicians points to a broader tension: unlike a drug for a rare, fatal disease, obesity affects tens of millions of Americans, and some doctors worry that expanded access programs for a lifestyle-related condition could invite pressure from many more patients than a company can reasonably accommodate ^[1]. Patients weighing whether to seek access through a doctor may want to understand that eligibility is limited and that the drug's full safety and effectiveness profile is still being established through ongoing phase 3 trials ^[2].

What happens next

Lilly said it is actively reviewing requests from health care providers under the new program ^[1][2]. The company has said it intends to file for FDA approval of retatrutide in the first quarter of 2027 ^[2]. Until that review process concludes, access outside of clinical trials will remain limited to patients who meet Lilly's specific medical criteria ^[2].